Compound Contains Two Or More C(=o)o Groups Patents (Class 514/547)
-
Patent number: 7754764Abstract: A seven-carbon fatty acid or derivative thereof has been identified as an excellent energy source for humans or human infants. A nutritional supplement suitable for humans or human infants comprising a seven carbon fatty acid chain compound or derivative thereof can be used to increase energy production derived from fatty acid metabolism. For example, administering a seven carbon fatty acid chain compound or derivative thereof can be used to accelerate the growth rate of a prematurely born human infant.Type: GrantFiled: February 21, 2003Date of Patent: July 13, 2010Assignee: Baylor Research InstituteInventor: Charles R. Roe
-
Publication number: 20100173002Abstract: Disclosed are microcapsules and methods for preparing and using them, as well as methods for improving various properties of microcapsules like impermeability.Type: ApplicationFiled: June 4, 2007Publication date: July 8, 2010Inventors: Jin Yulai, Colin James Barrow, Wei Zhang, Cuie Yan, Jonathan Michael Curtis, Shawn Moulton, Nancy Beatrice Diogbenou, Lesek Alexa Webber
-
Publication number: 20100172851Abstract: A composition and method for producing a beneficial effect on a subject's nerve associated with at least one of a cosmetic condition, a dermatological indication and a dental indication and another condition. The composition comprises a hydroxy-oligocarboxylic ester and is formulated for topical administration of the product to a subject to produce the beneficial effect. The method includes topically applying to the subject in a region where the beneficial effect is desired a hydroxy-oligocarboxylic ester in an amount effective to produce the beneficial effect.Type: ApplicationFiled: March 18, 2010Publication date: July 8, 2010Inventors: Ruey J. YU, Eugene J. VAN SCOTT
-
Patent number: 7750044Abstract: The present invention relates to a novel class of polymeric compounds having specific quaternized amine based upon a dimer acid reacted with an alkanolamine to make an ester quaternary compound. Dimer acid is a C-36 diacid having a cyclic structure and two amine groups that allow for the synthesis of a high molecular weight cationic compound which is extremely substantitive to human skin and are well tolerated by human tissue making them suitable for use preparation of barrier products for personal care applications. These materials are dimethylaminopropyl amine free, which is highly desirable in personal care applications.Type: GrantFiled: April 1, 2008Date of Patent: July 6, 2010Assignee: SurfaTech CorporationInventors: Kevin A. O'Lenick, Anthony J. O'Lenick, Jr.
-
Publication number: 20100166684Abstract: There is provided a novel water-in-oil type emulsified cosmetic comprising a diester of neopentylglycol with isononanoic acid. Said cosmetic exhibits not only the refreshed feeling on use without unfavorable stickiness after application, but also proper oily feeling. There are obtained good affinity to the skin, little occurrence of creasing and/or make-up deterioration, no oily sheen upon the elapse of long periods of time after application, and little irritation to the skin and excellent safety to the skin. In addition, the present cosmetic is able to be removed with commercially available cleansing agents. Moreover, the dispersibility of pigments as well as the storage stability is excellent. A water-in-oil type emulsified cosmetic comprising (A) 10 to 60 parts by mass of a diester represented by the following formula (I): (B) 1.0 to 11 parts by mass of a nonionic surfactant, (C) 0.3 to 11 parts by mass of an oil-soluble and/or water-soluble thickener, (D) 0.Type: ApplicationFiled: December 24, 2009Publication date: July 1, 2010Applicant: Kokyu Alcohol Kogyo Co., Ltd.Inventor: Yuki KOKEGUCHI
-
Patent number: 7745424Abstract: The present invention pertains to certain alkane diol derivatives (including, e.g., mono- and di-esters) of the formula R1—O-A-O—R2, wherein: A is a C2-10 alkylene group; R1 is independently a first hydroxy protecting group (e.g., an ester group); and, R2 is independently —H or a second hydroxy protecting group (e.g., an ester group); and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrug thereof, which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption.Type: GrantFiled: October 31, 2002Date of Patent: June 29, 2010Assignee: The Univeristy Court of the University of AberdeenInventors: Stuart H Ralston, Iain R Greig, Robert J Van't Hof, Kenneth J Armour
-
Patent number: 7745488Abstract: A composition and method for promoting neutrophil survival and activation such as the treatment of neutropenia arising as an undesirable side effect of chemotherapy and radiation therapy. A composition containing medium-chain fatty acids, such as Capri acid or caprylic acid, or salts or triglycerides thereof, or mono- or diglycerides or other analogues thereof or medium-chain triglycerides (MCT) is administered to a human or animal needing treatment in an amount sufficient to reduce or eliminate neutropenia. The composition is administered in an amount effective to treat the disorder. The methods are also useful in the management of bone narrow transplantation and in the treatment of various neutropenic diseases.Type: GrantFiled: April 18, 2002Date of Patent: June 29, 2010Assignee: Prometic Biosciences, Inc.Inventors: Lyne Gagnon, Jean Barabe, Pierre Laurin, Christopher Penney, Boulos Zacharie
-
Publication number: 20100158958Abstract: Gastric resistant film-forming compositions are described herein. The composition comprises a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent. Suitable gastric resistant natural polymers include polysaccharides such as pectin and pectin-like polymers. The film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (Softlet®) comprising an active agent and one or more pharmaceutically acceptable excipients. Alternatively, the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition. The compositions are not only gastric resistant but may also prevent gastric reflux associated with odor causing liquids, such as fish oil or garlic oil, encapsulated in a unit dosage form and esophageal irritation due to the reflux of irritant drugs delivered orally.Type: ApplicationFiled: March 3, 2010Publication date: June 24, 2010Inventor: Nachiappan Chidambaram
-
Publication number: 20100160409Abstract: The invention relates to compounds, which are suitable for coupling to pharmaceuticals, in particular biopharmaceuticals, in addition to conjugates from the compounds comprising biomolecules or pharmaceutically active substances. The inventive compounds are highly cross-linked and can be formed in a simple manner by using a central cross-linking module. The invention also relates to the use of conjugates as an improved formulation of pharmaceuticals and to the production thereof.Type: ApplicationFiled: August 31, 2006Publication date: June 24, 2010Inventors: Ralf Krahmer, Frank Leenders
-
Publication number: 20100144875Abstract: Compositions and methods for preventing, reducing, or delaying decline in one or more of cognitive function, motor function, cerebrovascular function, or behavior in animals, particularly geriatric animals, are disclosed. The compositions and methods utilize medium chain triglycerides.Type: ApplicationFiled: December 15, 2006Publication date: June 10, 2010Inventors: Brian T. Larson, Samuel T. Henderson, Matthew A. Roberts
-
Publication number: 20100143478Abstract: The invention provides methods of inhibiting inflammation and/or the complement cascade and/or the kinin cascade in a human or non-human animal patient, particularly in a wound (for example, a chronic ulcerous skin lesion) in a human or non-human mammal (particularly a human). The affected location of the patient is contacted with a hydrogel composition comprising a hydrophilic polymer carrying multiple pendant sulphonyl groups, optionally with multiple pendant carboxylic groups, on each polymer molecule.Type: ApplicationFiled: January 17, 2008Publication date: June 10, 2010Inventor: Hugh Semple Munro
-
System And Method For Reducing The Appearance Of Fine Lines And Wrinkles And Improving the Skin Tone
Publication number: 20100145255Abstract: The present invention provides a system for rejuvenating the skin, reducing the appearance of fine lines and wrinkles, and improving the skin tone, which includes both a topical composition and a phototherapy device. Specifically, the topical composition contains one or more skin rejuvenating agents selected from the group consisting of creatine, adenosine phosphate, acetyl carnitine, acetyl hexapeptide, and combinations thereof in a pharmaceutically or cosmetically acceptable carrier. The phototherapy device contains one or more light emitting diodes (LEDs) for emitting electromagnetic radiation effective for energizing the skin cells and enhancing skin absorption of the skin rejuvenating agents. More particularly, the topical composition is capable of transmitting at least 80% of the electromagnetic radiation emitted by the phototherapy device to the skin.Type: ApplicationFiled: November 18, 2009Publication date: June 10, 2010Inventors: Lavinia C. Popescu, Geoffrey Hawkins, Jack Lombardi, Barbara Anne Wolf -
Publication number: 20100143284Abstract: A water-in-oil type emulsion with a highly moisturizing effect on the skin has good emulsion stability and achieves a good feeling in use as a massage cream when a large amount of perfume is blended. The water-in-oil type emulsion includes the following components: (A) glyceryl monooleate, (B) a surfactant having branched chains in an alkyl group, (C) an aqueous component, (D) an oil component, and (E) a perfume component, Conditions (1) and (2) are met by the emulsion. Condition (1): the ratio of the sum of glyceryl monooleate (component (A)) and the surfactant having branched chains in an alkyl group (component (B)) with respect to a total composition is from 5 to 10% by mass. Condition (2): the ratio of perfume component (component (E)) with respect to the total composition is 0.3% by mass or more.Type: ApplicationFiled: May 14, 2008Publication date: June 10, 2010Applicant: SHISEIDO COMPANY LTD.Inventors: Kei Watanabe, Takayuki Sakiguchi, Takashi Teshigawara
-
Publication number: 20100144869Abstract: A novel use of conjugates of psychotropic drugs (e.g., antidepressants or anti-epileptic drugs) and organic acids such as GABA in the treatment of pain is disclosed. A novel GABA conjugate and uses thereof is also disclosed.Type: ApplicationFiled: July 17, 2007Publication date: June 10, 2010Inventors: Abraham Nudelman, Ada Rephaeli, Irit Gil-Ad, Abraham Weizman
-
Patent number: 7732171Abstract: A process is provided for the preparation of a compound of formula (1) wherein R and R? represent optionally substituted hydrocarbyl groups and X represents a hydrocarbyl linking group. The process comprises either the stereoselective reduction of the keto group in a dihydroxy keto precursor followed by selective esterification of a primary hydroxy, or selective esterification of a primary hydroxy of a dihydroxy keto precursor followed by stereoselective reduction of the keto group.Type: GrantFiled: July 23, 2008Date of Patent: June 8, 2010Assignee: AstraZeneca UK LimitedInventors: Andrew John Blacker, Christopher David Reeve, Robert Antony Holt
-
Patent number: 7732488Abstract: The invention relates to a process for decreasing the amount of environmental pollutants in a mixture comprising a fat or an oil, being edible or for use in cosmetics, the fat or oil containing the environmental pollutants, which process comprises the steps of adding a volatile working fluid to the mixture, where the volatile working fluid comprises at least one of a fatty acid ester, a fatty acid amide, a free fatty acid and a hydro-carbon, and subjecting the mixture with the added volatile working fluid to at least one stripping processing step, in which an amount of environmental pollutant present in the fat or oil, being edible or for use in cosmetics, is separated from the mixture together with the volatile working fluid. The present invention also relates to a volatile environmental pollutants decreasing working fluid, for use in decreasing an amount of environmental pollutants present in a fat or oil, being edible or for use in cosmetics.Type: GrantFiled: July 8, 2003Date of Patent: June 8, 2010Assignee: Pronova Biopharma Norge ASInventors: Harald Breivik, Olav Thorstad
-
Publication number: 20100137436Abstract: The invention relates to trans carotenoid salt compounds, methods for making them, methods for solubilizing them and uses thereof. These compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals including humans.Type: ApplicationFiled: January 25, 2010Publication date: June 3, 2010Applicant: Diffusion Pharmaceuticals LLCInventors: John L. Gainer, Raymond C. Grabiak
-
Publication number: 20100136089Abstract: The application of active ingredients, exemplified by GML, to absorbent fibers, such as rayon fibers, used in tampon manufacture at very low levels has been found to maintain efficacy in the inhibition of the production of toxic shock syndrome toxin one (TSST-1) produced by S. aureus without overtly killing the microorganism to achieve the desired reduction while avoiding undesired test results that suggest the presence of “impurities” in some jurisdictions.Type: ApplicationFiled: November 20, 2009Publication date: June 3, 2010Inventors: Linda M. PIERSON, Susan K. Brown-Skrobot, Ching-Yun M. Yang
-
Publication number: 20100130607Abstract: Methods of treating neurological disorders characterized by extensive demyelination and/or axonal loss are provided. Examples of such disorders include secondary progressive multiple sclerosis and Devic's disease. The disclosed methods include administering to a subject having such a disorder a therapeutically effective amount of, for example, dimethyl fumarate or monomethyl fumarate.Type: ApplicationFiled: February 7, 2008Publication date: May 27, 2010Inventor: Ralf Gold
-
Patent number: 7723386Abstract: A lipid-improving agent containing a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position of a triglyceride(s).Type: GrantFiled: March 26, 2004Date of Patent: May 25, 2010Assignee: Suntory Holdings LimitedInventors: Kengo Akimoto, Harukazu Fukami, Toshinao Goda
-
Publication number: 20100120755Abstract: Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity.Type: ApplicationFiled: January 14, 2010Publication date: May 13, 2010Applicants: Ramot At Tel Aviv University Ltd., Bar-Ilan UniversityInventors: Abraham Nudelman, Ada Rephaeli, Irit Gil-Ad, Abraham Weizman
-
Publication number: 20100113594Abstract: A pesticidal composition containing: 4-methoxymethyl-2,3,5,6-tetrafluorobenzyl 3-(2-cyano-1-propenyl)-2,2-dimethylcyclopropanecarboxylate, a saturated hydrocarbon having an initial boiling point of 150 C or higher and a 95%-distillation temperature of 300 C or lower, and at least one alkyl carboxylate ester selected from the group consisting of the following esters (i) to (iii): (i) alkyl alkylcarboxylate esters having 12 to 20 carbon atoms, (ii) dialkyl dicarboxylate esters having 12 to 20 carbon atoms, and (iii) trialkyl acetylcitrate esters having 12 to 20 carbon atoms; has an excellent pesticidal activity.Type: ApplicationFiled: March 3, 2008Publication date: May 6, 2010Applicant: SUMITOMO CHEMICAL COMPANY LIMITEDInventors: Masahiro Yamada, Yoshito Tanaka
-
Publication number: 20100113595Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of ?-linolenic acid, dihomo-?-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-?1 levels in the patient to therapeutic levels.Type: ApplicationFiled: December 31, 2009Publication date: May 6, 2010Applicant: BTG International LimitedInventors: Lawrence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
-
Publication number: 20100113593Abstract: The invention relates to water-free, topically applicable agents for treating, nail problems caused by mycoses, and for nail care, said agents containing at least one C1-C4 alkyl ester of lactic acid, malic acid, tartaric acid or citric acid and physiologically compatible auxiliary substances. The agents according to the invention can also be used in veterinary medicine for treating fungal infections of hooves, claws and talons of pets, working animals and wild animals in captivity.Type: ApplicationFiled: April 3, 2008Publication date: May 6, 2010Inventor: Hans Meyer
-
Patent number: 7705048Abstract: A seven-carbon fatty acid or derivative thereof has been identified as an excellent energy source for humans or human infants. A nutritional supplement suitable for humans or human infants comprising a seven carbon fatty acid chain compound or derivative thereof can be used to increase energy production derived from fatty acid metabolism. For example, administering a seven carbon fatty acid chain compound or derivative thereof can be used to accelerate the growth rate of a prematurely born human infant.Type: GrantFiled: December 30, 2003Date of Patent: April 27, 2010Inventor: Charles R. Roe
-
Publication number: 20100098766Abstract: Use of a micro-emulsion comprising at least one surfactant having a HLB value between 5 and 15, at least one lipophilic substance, and water for the preparation of a formulation for the treatment of adipose tissue disease and/or condition with improved bioavailability and good release behaviour of active substances.Type: ApplicationFiled: March 7, 2008Publication date: April 22, 2010Applicant: MERZ PHARMA Gmbh & CO. KGaAInventors: Edgar Mentrup, Rainer Pooth, Thomas Wimmer, Sigrid Drewes
-
Publication number: 20100093856Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt. -% of the acyl-groups of said diglycerides, are eicosapentaenoic acid (EPA) groups and/or docosahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.Type: ApplicationFiled: September 19, 2007Publication date: April 15, 2010Inventors: Richard J. Deckelbaum, Yvon Carpentier
-
Publication number: 20100087525Abstract: The present invention relates to a stereoselective enzymatic synthesis of (S) or (R)-iso-butyl-glutaric ester, an intermediate of S-Pregabalin.Type: ApplicationFiled: June 23, 2009Publication date: April 8, 2010Inventors: Lilach Hedvati, Greta Sterimbaum, Yuriy Raizi, Rahamin Aminov
-
Publication number: 20100087319Abstract: The invention relates to agrochemical preparations containing (a) active ingredients and (b) esters of hydroxycarboxylic acids.Type: ApplicationFiled: April 12, 2008Publication date: April 8, 2010Applicant: COGNIS IP MANAGEMENT GMBHInventors: Hans-Georg Mainx, Ansgar Behler
-
Patent number: 7691906Abstract: A composition for use as a medicament, functional food or nutritional product is described which comprises at least one lipid wherein the lipid provides greater than 35% total energy of the composition. A preferred embodiment comprises a n-6/n-3 fatty acid ratio of about 2/1 to 7/1. In addition, a method of preparing the composition; use of the composition in the manufacture of a medicament, functional food or nutritional product; and a method of treatment or treatment or prevention of sepsis or inflammatory shock which comprises administering an effective amount of the composition are described.Type: GrantFiled: August 16, 2005Date of Patent: April 6, 2010Assignees: Nestec S.A., Institut de la Research AgronomiqueInventors: Marco Turini, Claudia Roessle, Denis Breuille, Gayle Crozier-Willi, Paul André Finot, Myriam Richelle, Guy Dutot, Christiane Obled
-
Publication number: 20100080856Abstract: A composition and a method for administering the composition to a patient in order to accelerate wound healing, particularly postoperative wound healing. The composition, which essentially comprises ornithine ?-ketoglutarate, is water-soluble and formulated for oral administration in single-dose packets. The method for using the composition for promoting wound healing includes the step of administering the composition to a patient preoperatively as well as-postoperatively in accordance with a prescribed protocol. The composition may be customized to include one or more additional agents that are effective for promoting nutritional health and/or treating a particular medical problem. The composition may also be taken daily by athletes to minimize the healing time of closed wounds such as muscle or tendon tears that occur during participation in sports, even when the symptoms of such injury are subclinical.Type: ApplicationFiled: September 26, 2008Publication date: April 1, 2010Inventor: Peter D. Costantino
-
Publication number: 20100069490Abstract: The invention proposes a composition for pharmaceutical use containing as active principles triethyl citrate and adapalene in quantities efficacious for use in the treatment of cutaneous pathologies of inflammatory origin, caused by bacterial infections or altered lipid metabolism, both in the treatment of chronologic and photo induced cutaneous ageing,Type: ApplicationFiled: November 5, 2007Publication date: March 18, 2010Inventor: Gianfranco de Paoli Ambrosi
-
Publication number: 20100069446Abstract: The present invention is directed to a derivative comprised of an L-Threonine bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. The derivative has the same utility as the drug from which it is made, but it has enhanced therapeutic properties. In fact, the derivatives of the present invention enhance at least one or more therapeutic qualities, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.Type: ApplicationFiled: September 10, 2009Publication date: March 18, 2010Applicant: SIGNATURE R&D HOLDINGSInventor: V. Ravi Chandran
-
Publication number: 20100062055Abstract: Novel nitric-oxide releasing lipid molecules are provided which comprise a lipid molecule selected from (a) phosphoglycerides, (b) lipids having a sphingosine base as a backbone, (c) monoacylglyerols, (d) diacylglycerols, (e) glycosylacylglycerols, and (f) sterol compounds of the formula: where R is a branched aliphatic chain of eight or more carbon atoms, wherein the lipid molecule is provided with a nitric-oxide containing group which comprises (a) a —S—N?O moiety, (b) a —O—N?O moiety, or (c) a moiety. Also provided are methods of forming such nitric oxide releasing lipid molecules. Various pharmaceutical compositions, topical liquids and drug delivery systems comprising the nitric-oxide releasing lipid molecules are also described.Type: ApplicationFiled: November 17, 2009Publication date: March 11, 2010Applicant: BOSTON SCIENTIFIC SCIMED, INC.Inventors: Robert A. Herrmann, Wendy Naimark
-
Publication number: 20100063147Abstract: The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.Type: ApplicationFiled: December 3, 2007Publication date: March 11, 2010Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Alexandra Durr, Fanny Mochel
-
Publication number: 20100063135Abstract: Polyethylene glycol (PEG)-lipid conjugates, polyethylene glycol (PEG)-lipid conjugate based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.Type: ApplicationFiled: September 10, 2009Publication date: March 11, 2010Applicant: ABBOTT LABORATORIESInventors: Prasad A. Dande, Todd M. Hansen, Robert D. Hubbard, William E. Kohlbrenner, Leiming Li, Aparna V. Sarthy, Yu Shen, Lu Tian, Carol K. Wada, Xiaobin Zhao
-
Publication number: 20100048651Abstract: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.Type: ApplicationFiled: August 19, 2009Publication date: February 25, 2010Applicant: XenoPort, Inc.Inventors: Archana Gangakhedkar, Xuedong Dai, Noa Zerangue, Peter A. Virsik
-
Patent number: 7666910Abstract: A method of stabilizing and potentiating action of molecules of known anti-angiogenic substances such as ANGIOSTATIN® or ENDOSTATIN® by using in coupling conjugation with cis-unsaturated fatty acids (c-UFAs) in the treatment of cell proliferative disorders uses c-UFAs chosen from linoleic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and cis-parinaric acid in predetermined quantities. Preferably, the c-UFAs are in the form of polyunsaturated fatty acids (PUFAs). Uncontrolled or undesirable angiogenic activity promotes cell proliferative disorders and tumor growth, which can be inhibited by the selective use of PUFAs with anti-angiogenic substances used selectively in conjunction with predetermined anti-cancer drugs. For a non-glioma type of cell proliferation disorder, a sodium, potassium or lithium salt of a PUFA is preferred to form an admixture with an anti-angiogenic substance.Type: GrantFiled: February 27, 2002Date of Patent: February 23, 2010Inventor: Undurti Narasimha Das
-
Publication number: 20100041751Abstract: Methods for the reduction of mitochondrial oxidative damage and improved mitochondrial efficiency in an animal by administration of medium chain triglycerides or prodrug of medium chain triglycerides to the animal are provided.Type: ApplicationFiled: October 23, 2009Publication date: February 18, 2010Applicant: ACCERA, INC.Inventor: Samuel T. Henderson
-
Publication number: 20100040662Abstract: Fixation devices for tissue repair, for example sutures, surgical arrows, staples, darts, bolts, screws, buttons, anchors, nails, rivets, or barbed devices comprise at least one of angiogenic material; angiogenic precursor material which is capable of breaking down in vivo to form angiogenic material; or tissue-engineered material, which tissue-engineered material is capable of producing angiogenic material. In a preferred form, the material is incorporated into a polymer matrix having predetermined hydrophobicity to allow controlled release of angiogenic materials such as butyric or hydroxybutyric acid or salts thereof. Polymer matrix compositions comprising angiogenic materials and methods for tissue repair are also provided.Type: ApplicationFiled: June 15, 2009Publication date: February 18, 2010Inventors: Nicholas J. Cotton, Emma J. Wright, Steven W. Astorino, Saad Ali
-
Patent number: 7662853Abstract: The uses of mono acetyl diacyl glycerol derivatives extracted from deer antler for immunomodulating agent disclosed. Medical supplies and health foods containing the same as an effective ingredient also disclosed. Mono acetyl diacyl glycerol derivatives shows significantly effect for immuno modulation including immune enhancing. In the case of inducing cancer in a hamster by injecting cancer cell line, cancer development was delayed by activating lymphocytes, monocytes, and dendritic cells that are important factors to promote immunity and apoptosis of cancer cell was induced by promoting cytotoxicity of immune cell against cancer cell. Also in the case of mouse induced septic shock, it shows 100% survival rate even after lapse of 120 hours by control of immune function and suppression effect apoptosis.Type: GrantFiled: April 22, 2005Date of Patent: February 16, 2010Inventor: Sang-Hee Kim
-
Patent number: 7658937Abstract: A process for the preparation of hydroxyl substituted anthraquinones is described. The process couples a phthalic anhydride (substituted or unsubstituted) to benzene ring moiety substituted with at least two hydroxyl groups. Remaining hydroxy groups were converted to methoxy groups in some anthraquinones. The compounds are particularly useful for the treatment of parasitic diseases. Also, a method of treating or preventing malaria, filariasis schistosomiasis and other parasitic diseases using anthraquinones.Type: GrantFiled: March 7, 2005Date of Patent: February 9, 2010Assignee: Board of Trustees of Michigan State UniversityInventors: Muraleedharan G. Nair, Mugunthu R. Dhananjeyan, Michael A. Kron, Youli P. Milev
-
Patent number: 7655698Abstract: Use of L-carnitine and/or of one or more alkanoyl L-carnitines or one of their pharmaceutically acceptable salts for the preparation of an ophthalmic physiological supplement or medicament in the form of eye-drops, for the treatment of corneal diseases.Type: GrantFiled: December 14, 2006Date of Patent: February 2, 2010Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Aleardo Koverech, Nicola Pescosolido
-
Patent number: 7649103Abstract: Long-chain unsaturated oxygenated compounds and their use in the therapeutical, cosmetic and nutraceutical field.Type: GrantFiled: June 16, 2003Date of Patent: January 19, 2010Assignee: Medestea Research and Production S.r.l.Inventor: Giancarlo Cravotto
-
Patent number: 7648711Abstract: A sustained release formulation by using dimeticone as the dispersion medium, which includes active ingredient (e.g., drugs against parasites, insecticides, NSAIDs, antibiotics, sex hormone like agents or oily soluble vitamins) and dimeticone as the medium. Suitable stabilizer, antioxidant, local analgesics and material for sustained release may be added. The formulation is bio-compatible, stable and injectable.Type: GrantFiled: October 8, 2003Date of Patent: January 19, 2010Inventors: Yuwan Wang, Zhende Pan, Xiaoxi Dai
-
Patent number: 7645795Abstract: The administration of nutritional supplements such as phosphatidylcholine; linoleic acid and alpha linolenic acid in an approximately 4:1 (v/v) ratio; and mineral supplements provides an effective method for the treatment of ALS. Subjects presenting with symptoms indicative of ALS can therefore be treated with these nutritional supplements to inhibit progression of ALS. Subjects at risk for developing ALS can also be treated with these nutritional supplements to delay the onset of ALS symptoms.Type: GrantFiled: September 21, 2004Date of Patent: January 12, 2010Assignee: BodyBio, IncInventors: Patricia Kane, Edward Kane
-
Patent number: 7645794Abstract: A nutritional supplement comprising at least a therapeutically effective amount of ethyl pyruvate and a therapeutically effective amount of at least one ?-hydroxy branched-chain amino acid metabolite is provided by the present invention. The ingredients of the present nutritional supplement substantially simultaneously act to induce a anabolically-favorable state for muscle by substantially simultaneously maintaining blood and muscle physiological pH levels as well as increasing cellular concentrations of branched-chain amino acids. Both a composition and a method are provided by the present disclosure.Type: GrantFiled: September 11, 2007Date of Patent: January 12, 2010Assignee: Multi Formulations Ltd.Inventors: Michele Molino, Joseph MacDougall
-
Patent number: 7642286Abstract: Stabilized pharmaceutical preparations containing a drug in which is sensitive to a low pH environment, such as pravastatin are disclosed in which pravastatin degradations is prevented with a buffering agent. The basic excipient enhances storage stability.Type: GrantFiled: June 5, 2002Date of Patent: January 5, 2010Assignee: Andrx Pharmaceuticals, Inc.Inventors: Boyong Li, Avinash Nangia, Aaron Dely, David Wong
-
Patent number: 7642287Abstract: The invention provides novel omega-3 oil solutions of one or more statins. These solutions are readily bioavailable. Notably, because the solutions of the invention contain an omega-3 oil as the major ingredient, they not only provide an antihypercholesterolemic effect due to the statin active ingredient, they also provide recommended daily dosages of omega-3 oils (i.e., approximately 1 gram of omega-3 oil per day), or a portion thereof. The invention also provides novel salts of one or more statins.Type: GrantFiled: August 5, 2005Date of Patent: January 5, 2010Assignee: Transform Pharmaceuticals, Inc.Inventors: Hector Guzman, Julius Remenar, Orn Almarsson
-
Publication number: 20090326069Abstract: Therapeutic and cosmetic treatments are performed through the application of azelaic acid ester compositions to patients suffering from or exhibiting tissue inflammation. The diagnosis, characterization and treatment of a patient suffering from or exhibiting tissue inflammation may be enhanced by using selected proteinaceous biomarkers obtained from analysis of said markers by means of multiplexed immunoassay and comparison to the biomarker levels of healthy tissue.Type: ApplicationFiled: June 30, 2009Publication date: December 31, 2009Inventors: Robert T. Streeper, Elzbieta Izbicka